Drug Profile
Research programme: FimH antagonists - Enterome Bioscience
Latest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Developer Enterome
- Class Bacterial proteins; Small molecules
- Mechanism of Action Adhesion receptor antagonists; Gastrointestinal microbiome modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 01 Sep 2023 Discontinued - Preclinical for Inflammatory bowel diseases in France (unspecified route) (Enterome Bioscience pipeline; September 2023)
- 28 May 2020 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in France
- 20 Apr 2016 Preclinical trials in Inflammatory bowel disease in France (unspecified route) before April 2016